Regulation of adverse remodelling by osteopontin in a genetic heart failure model

Stelios Psarras1, Manolis Mavroidis, Despina Sanoudou

  • 1Cell Biology Division, Center of Basic Research I, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, Athens 11527, Greece.

European Heart Journal
|April 29, 2011
PubMed
Abstract

Insights

Desmin deficiency causes heart issues, leading to inflammation and osteopontin (OPN) overexpression. Removing OPN significantly improves cardiac function and reduces fibrosis in desmin-deficient mice.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Immunology

Background:

  • Desmin deficiency (des(-/-)) in mice causes myocardial degeneration, fibrosis, and osteopontin (OPN) overexpression.
  • Understanding the molecular mechanisms behind cardiac remodeling in des(-/-) mice is crucial.

Purpose of the Study:

  • To investigate the molecular and cellular events regulating cardiac remodeling in des(-/-) mice.
  • To determine the role of osteopontin (OPN) in this process.

Main Methods:

  • In situ hybridization, histology, and immunostaining to identify OPN source.
  • RNA profiling to analyze gene expression changes in des(-/-) myocardium.
  • Generation and comparison of des(-/-)OPN(-/-) mice with des(-/-) mice for cardiac function and remodeling.

Main Results:

  • Osteopontin (OPN) is primarily overexpressed by inflammatory cells, specifically macrophages, in the degenerating des(-/-) myocardium.
  • Desmin-deficient mice lacking OPN (des(-/-)OPN(-/-)) exhibited a 53% improvement in left ventricular function and up to 44% reduction in fibrosis.
  • The reduced fibrosis in des(-/-)OPN(-/-) mice was associated with decreased galectin-3 levels and impaired macrophage secretion.

Conclusions:

  • Cardiomyocyte death in desmin deficiency triggers inflammation and the overexpression of remodeling modulators.
  • Osteopontin (OPN) significantly drives adverse cardiac remodeling in desmin deficiency.
  • OPN's pro-remodeling effects involve potentiating galectin-3 upregulation and secretion.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...